NEW YORK--(BUSINESS WIRE)--Remedy Pharmaceuticals, a privately-held, Phase 3-ready pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that the Company appointed Thomas MacAllister as Vice President of Research and Development, and General Counsel.
“As we begin preparations for commencement later this year of our Phase 3 clinical trial in patients with large hemispheric stroke, Tom’s wealth of CNS-related clinical trial experience will be indispensable,” states Sven Jacobson, CEO of Remedy Pharmaceuticals. “We’re therefore delighted to welcome him to the senior management team.”
Read More: http://www.businesswire.com/news/home/20160315005038/en/Remedy-Pharmaceuticals-Appoints-Thomas-MacAllister-Vice-President
Remedy Pharmaceuticals Appoints Thomas MacAllister as Vice President of Research and Development and General Counsel
Via: Business Wire